Sotera Health — Sterilization Infrastructure and the Litigation Discount

Sotera Health operates three segments:

• Sterigenics — the largest segment by revenue, providing contract ethylene oxide, gamma, and electron-beam sterilization across a global network of facilities serving medical device, pharmaceutical, and food-safety customers.
• Nordion — supplies cobalt-60 and medical isotopes, including for cancer therapy, and holds a leading global position in gamma-source supply.
• Nelson Labs — a microbiology, analytical chemistry, and consulting business that validates sterilization processes and supports regulatory submissions.

How it makes money: The majority of revenue is recurring, fee-for-service contract sterilization billed per pallet or per cycle, often under multi-year agreements with device OEMs. Nordion revenue is tied to isotope supply contracts, which are long-dated and price-escalated. Labs revenue is project- and program-based with high renewal rates.

Customers and scale: The customer base is concentrated among large medical device and pharmaceutical manufacturers, with the top customers accounting for a meaningful share of revenue — a concentration risk offset by very high switching costs. Total revenue is in the low-to-mid $1B range with adjusted EBITDA margins in the mid-30s, reflecting the capital intensity and regulatory barriers of the business.

Near term (12-24 months):

• Volume recovery in elective-procedure-linked device categories, which drives sterilization cycle counts.
• Price increases contractually embedded in multi-year agreements, typically in the low-to-mid single digits.
• Nelson Labs program wins as device makers refresh validation documentation.
• Partial unwind of litigation reserve releases if settlements come in below expectations.

Medium term (3-5 years):

• Capacity expansion at existing sites, which carries higher incremental returns than greenfield builds.
• Shift toward EtO abatement technology investment — a cost headwind but also a competitive moat, since smaller operators cannot fund the upgrades.
• Medical isotope demand growth from oncology therapeutics, where Nordion has a structural supply position.
• Deleveraging-driven EPS accretion as interest expense declines.

We model consolidated revenue growth in the mid-single digits annually through 2028, with adjusted EBITDA margin expansion of roughly 50-100 bps and EPS growth in the low-to-mid teens, aided by debt paydown.

Estimates are analyst projections; historical figures are approximate and rounded.

The model is driven by three levers: mid-single-digit organic revenue growth from contractual price escalators and procedure volume, stable-to-slightly-expanding margins as Nelson Labs mix improves, and a declining interest burden as free cash flow is directed to debt reduction. Trailing EPS of $0.57 implies the company is already operating near the middle of this trajectory. The key sensitivity is litigation funding: any cash settlement materially above reserve would push leverage back above 4x and delay the deleveraging story by 12-18 months.

The outsourced sterilization market is estimated in the $5-6B range globally and growing in the mid-single digits, with the broader sterilization services and validation market (including lab testing) closer to $8-10B. Barriers are unusually high: radioactive source licensing, environmental permits for EtO, FDA facility registration, and customer qualification cycles that can take 12-24 months.

Competitive positioning: Sotera is the clear scale leader. Its gamma capacity via Nordion is effectively a duopoly with a small number of alternative isotope suppliers, and its EtO footprint is the largest in North America. The principal competitive threat is not price but modality substitution — device makers evaluating alternative sterilization methods (x-ray, supercritical CO2, nitrogen dioxide) to reduce EtO dependence. We view substitution as gradual and limited to a subset of products.

Named comparables:

• Steris plc — sterilization equipment and services, infection prevention; trades at a premium multiple reflecting no litigation overhang.
• Thermo Fisher Scientific — owns Patheon and clinical services; broader but a reference point for regulated services multiples.
• Charles River Laboratories — lab testing and research services with comparable regulatory moat characteristics.
• Ecolab — contamination-control and life-sciences services, a margin and returns benchmark.

DCF discussion: A ten-year DCF using a WACC of approximately 9.5-10.5% (elevated by the 1.93 beta and leverage) and terminal growth of 2.5-3.0% produces an intrinsic value range of roughly $17-22 per share under base-case litigation assumptions. The wide range reflects legal-outcome uncertainty more than operating uncertainty: shifting assumed total settlement cost by $200M moves equity value by roughly $0.70 per share. Under a favorable resolution scenario, fair value approaches the high end; under an adverse scenario with equity issuance, the low end or below.

Comparable multiples:

Sotera trades at a discount of roughly 30-45% to the peer group on EV/EBITDA. Some discount is warranted for leverage and legal risk; we estimate the appropriate discount at 15-25%, implying fair value in the high-teens to low-twenties per share.

• Litigation outcomes: EtO tort claims could resolve above reserved amounts, requiring additional cash outlays or, in an adverse scenario, equity issuance that dilutes existing holders.
• Regulatory action on EtO: EPA or state-level restrictions on ethylene oxide emissions could force facility closures or costly retrofits, reducing capacity and revenue.
• Leverage and refinancing: With net leverage in the mid-3x range and a 1.93 beta, a rise in rates or a credit-rating downgrade would raise interest costs and constrain the deleveraging path.
• Customer concentration: A small number of large device OEMs account for a significant share of revenue; loss of a major contract or a customer insourcing sterilization would be material.
• Modality substitution: Accelerated adoption of non-EtO, non-gamma sterilization technologies could erode long-term volume growth and pricing power.
• Trading liquidity risk: Short interest of 16.09M shares (6.51% of float) against 2.30M average volume creates squeeze and air-pocket risk in both directions.